// App-Quantinova.ai

1042 : Development of AEB1102, an engineered human arginase 1 for patients with solid tumors

Researchers

Presenter

  • Scott W. Rowlinson

Principal Investigators

  • Susan E. Alters

  • Giulia Agnello

  • Joseph Tyler

  • Ann Lowe

  • Mauri Okamoto-Kearney

  • Dale Johnson

  • Everett Stone

  • George Georgiou

  • David G. Lowe

Medical Centers

  • Aeglea Biotherapuetics, Austin, TX

  • The University of Texas at Austin, Austin, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

Biomarkers

  • Argininosuccinate Synthase 1

Drug/Treatment

  • Asparaginase

  • Arginine hydrochloride

  • AEB1102

  • PEGylated recombinant human arginase 1

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved